ResMedMEX:RMD 99 Days Payable is 44.18 as of Mar. 2026, which is 23% above its 10-year median of 35.87. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,059.75 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, ResMed ranks worse than 71.45% on this metric.
ResMed's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN4,719 Mil. ResMed's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN9,745 Mil.
Hence, ResMed's Days Payable for the
three
months ended in Mar. 2026 was 44.18.
The historical rank and industry rank for ResMed's Days Payable or its related term are showing as below:
MEX:RMD'
s Days Payable Range Over the Past 10 Years
Min: 30.3 Med: 35.87 Max: 45.02
Current: 44.31
During the past 13 years, ResMed's highest Days Payable was 45.02. The lowest was 30.30. And the median was 35.87.
MEX:RMD's Days Payable is ranked worse than 71.45% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs MEX:RMD: 44.31
ResMed's Days Payable
increased
from Mar. 2025 (38.84) to Mar. 2026 (44.18).
It may suggest that ResMeddelayed paying its suppliers.
ResMed Days Payable Related Terms
ResMed Days Payable Historical Data
* Premium members only.
The historical data trend for ResMed's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RMD vs MDLN, WST, BDX: Days Payable Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Days Payable distribution charts can be found below:
* The bar in red indicates where ResMed's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ResMed's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (MEX:RMD) has a Days Payable of 44.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ResMed and its competitors. This is 23% above median its historical median of 35.87. Over the past decade, ResMed's Days Payable has ranged from 30.30 to 45.02. According to the industry distribution chart, ResMed ranks #568 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 71.4%.
Is ResMed's Days Payable too high?
ResMed's current Days Payable of 44.18 is 23% above median its 10-year median of 35.87. Over the past 10 years, this metric has ranged from a low of 30.30 to a high of 45.02. The Medical Devices & Instruments industry median Days Payable is 68.07. ResMed's value of 44.18 is 35.1% below this industry median. Based on the distribution chart, ResMed ranks #568 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, ResMed has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Days Payable compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #568 out of 795 companies for Days Payable. This places ResMed in the lower half of its industry. The industry median Days Payable is 68.07. ResMed's value of 44.18 is 35.1% below this benchmark. Historically, ResMed's own Days Payable has ranged from 30.30 to 45.02 over the past decade. While the company's 10-year median is 35.87 vs. the industry median of 68.07, ResMed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Days Payable of 44.18 is 35.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Days Payable is 44.18, which is 23% above median its own 10-year median of 35.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN5,059.75, compared to a current price of MXN3,716.10 — trading 26.6% below its estimated fair value. The current Days Payable is 44.18, which is 23% above median its 10-year median of 35.87 and 35.1% below the Medical Devices & Instruments industry median of 68.07. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ResMed (MEX:RMD), the current Days Payable is 44.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 26.6% below its estimated GF Value™ of MXN5,059.75.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for MEX:RMD:
Days Payable: 44.18 (23% above median its 10-year median of 35.87)
GF Value™: MXN5,059.75 vs. price of MXN3,716.10 (26.6% below fair value)
Industry Position: 35.1% below the Medical Devices & Instruments median (#568 of 795)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
